The immunogenicity to the first anti-TNF therapy determines the outcome of switching to a second anti-TNF therapy in spondyloarthritis patients
Arthritis Research & Therapy2013Vol. 15(4), pp. R79–R79
Citations Over TimeTop 10% of 2013 papers
Chamaida Plasencia, Dora Pascual‐Salcedo, Sara García, L. Lojo, Laura Nuño, Alejandro Villalba, Diana Peiteado, F. Arribas, Jesús Díez‐Manglano, M. T. López-Casla, E. Martín‐Mola, Alejandro Balsa
Abstract
In SpA the failure to respond to the first anti-TNF drug due to the presence of ADA predicts a better clinical response to a second anti-TNF drug.
Related Papers
- → Medication adherence and persistence in the treatment of rheumatoid arthritis with adalimumab and etanercept. Six years of analysis(2014)9 cited
- → Paradoxical worsening of psoriasis when switching from etanercept to adalimumab: A case series(2010)18 cited
- → SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB(2017)14 cited
- The efficacy of etanercept in treatment of ankylosing spondylitis and effect of etanercept on S-CTX level(2015)
- → Effect of functional exercise with etanercept therapy on ankylosing spondylitis(2011)